VISCHER advises Versantis AG, a Zurich based start-up biotech company, which develops products for the diagnosis, prevention, and treatment of liver diseases. The financing round of CHF 4.4 million was led by Redalpine Venture Partners, with the participation of Altus Partners, HealthEquity, Occident Group, Zürcher Kantonalbank and private investors.
The team at VISCHER was led by Matthias Staehelin with Sebastian Flückiger (both Corporate)